Mesenchymal-Stem-Cell-Based Strategies for Retinal Diseases

Retinal diseases are major causes of irreversible vision loss and blindness. Despite extensive research into their pathophysiology and etiology, pharmacotherapy effectiveness and surgical outcomes remain poor. Based largely on numerous preclinical studies, administration of mesenchymal stem cells (MSCs) as a therapeutic strategy for retinal diseases holds great promise, and various approaches have been applied to the therapies. However, hindered by the retinal barriers, the initial vision for the stem cell replacement strategy fails to achieve the anticipated effect and has now been questioned. Accumulating evidence now suggests that the paracrine effect may play a dominant role in MSC-based treatment, and MSC-derived extracellular vesicles emerge as a novel compelling alternative for cell-free therapy. This review summarizes the therapeutic potential and current strategies of this fascinating class of cells in retinal degeneration and other retinal dysfunctions

High-temperature dielectric properties and pyrolysis reduction characteristics of different biomass-pyrolusite mixtures in microwave field

Abstract Exploring the dielectric properties of mineral-biomass mixtures is fundamental to the coupled application with biomass pyrolysis and microwave technology to mineral reduction. In this work, the microwave dielectric properties of five pyrolusite-biomass mixtures were measured by resonant cavity perturbation technique and the pyrolysis reduction characteristics were systematically investigated, including poplar, pine, ageratina adenophora, rapeseed shell and walnut shell. Results indicated that the dielectric properties commonalities of five mixtures with temperature represented by increasing firstly, dropping intensely and finally rising slightly, with excellent responsiveness to microwaves; which the change trend was mainly attributed to the crystal transformation of amorphous MnO₂ and pyrolusite reduction reactions by biomass pyrolysis. Meanwhile, the heating characteristics successfully matched the dielectric properties of the mixtures, and the pyrolusite reduction process by biomass can be divided into two stages: biomass pyrolysis and pyrolusite reduction. The work highlights the universal feasibility of the novel coupled method for mineral reduction

Kinetics of Arsenic Removal in Waste Acid by the Combination of CuSO4 and Zero-Valent Iron

In this study, we investigated the kinetics of arsenic removal from waste acid by the combination of zero-valent iron (ZVI) and CuSO4. ZVI samples were characterized by X-ray diffraction and scanning electron microscopy before and after arsenic removal; the results showed that after the arsenic removal reaction, As2O3 and magnetite phases were detected on the surface of these samples. Kinetic studies were carried out under different reaction temperatures, with different CuSO4 concentrations, and with different iron to arsenic molar ratios (Fe/As). The kinetic data of the arsenic removal were fitted to different kinetic models. The fitting results showed that the arsenic removal process could be described by the shrinking core model, controlled by residual layer diffusion. The apparent activation energy of the reaction was 9.0628 kJ/mol, the reaction order with the CuSO4 concentrations was −0.12681, and the reaction order with the molar ratio of iron to arsenic (Fe/As) was 3.152

Peroxidase-mimicking evodiamine/indocyanine green nanoliposomes for multimodal imaging-guided theranostics for oral squamous cell carcinoma

Here, evodiamine (EVO) and the photosensitizer indocyanine green (ICG) were integrated into a liposomal nanoplatform for noninvasive diagnostic imaging and combinatorial therapy against oral squamous cell carcinoma (OSCC). EVO, as an active component extracted from traditional Chinese medicine, not only functioned as an antitumor chemotherapeutic agent but was also capable of 68Ga-chelation, thus working as a contrast agent for positron emission tomography/computed tomography (PET/CT) imaging. Moreover, EVO could exhibit peroxidase-like catalytic activity, converting endogenous tumor H2O2 into cytotoxic reactive oxygen species (ROS), enabling Chemo catalytic therapy beyond the well-known chemotherapy effect of EVO. As proven by in vitro and in vivo experiments, guided by optical imaging and PET/CT imaging, we show that the theragnostic liposomes have a significant inhibiting effect on in situ tongue tumor through photodynamic therapy combined with chemodynamic chemotherapy

Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial

Abstract Background We aimed to investigate the anatomical features of optical coherence tomography (OCT) and vitreous cytokine levels as predictors of outcomes of combined phacovitrectomy with intravitreal dexamethasone (DEX) implants for idiopathic epiretinal membrane (iERM) treatment. Methods A prospective, single-masked, randomized, controlled clinical trial included 48 eyes. They were randomly assigned in a 1:1 ratio to undergo the DEX group (combined phacovitrectomy with ERM peeling and Ozurdex implantation) and control group (phacovitrectomy only). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were assessed at 1 d, 1 week, 1 month, and 3 months. The structural features of OCT before surgery were analysed for stratified analysis. Baseline soluble CD14 (sCD14) and sCD163 levels in the vitreous fluid were measured using ELISA. Results BCVA and CMT were not significantly different in the DEX and control groups. Eyes with hyperreflective foci (HRF) at baseline achieved better BCVA (P time*group=0.746; P group=0.043, Wald χ²=7.869) and lower CMT (Ptime*group = 0.079; Pgroup = 0.001, Wald χ²=6.774) responses to DEX during follow-up. In all patients, the mean vitreous level of sCD163 in eyes with HRF was significantly higher than that in eyes without HRF (P = 0.036, Z=-2.093) at baseline. In the DEX group, higher sCD163 predicted greater reduction in CMT from baseline to 1 month (r = 0.470, P = 0.049). Conclusions We found that intraoperative DEX implantation did not have beneficial effects on BCVA and CMT over a 3-month period in all patients with iERM, implying that the use of DEX for all iERM is not recommended. In contrast, for those with HRF on OCT responded better to DEX implants at the 3-month follow-up and thier vitreous fluid expressed higher levels of sCD163 at baseline. These data support the hypothesis that DEX implants may be particularly effective in treating cases where ERM is secondary to inflammation. Trial registration The trail has been registered at Chinese Clinical Trail Registry( https://www.chictr.org.cn ) on 2021/03/12 (ChiCTR2100044228). And all patients in the article were enrolled after registration

Effects of Organic Compounds on Ni/AlLaCe Catalysts for Ammonia Decomposition to Hydrogen

Ammonia has attracted extensive attention from scholars due to its high energy density and hydrogen content. In this work, we synthesized a series of Ni-based catalysts by an impregnation method to investigate the influence of organic compounds on Ni/AlLaCe catalysts for NH3 decomposition. The effects of different organic compounds like β-cyclodextrin (β-CD), citric acid (CA), and poly(vinylpyrrolidone) (PVP) on the catalyst structure and performance have been examined through a series of characterizations. Experimental results indicated that citric acid significantly affects the size of the active metal particles and promotes metal–support interaction compared to other organic compounds. At the same time, the introduction of citric acid increased the number of strongly basic sites and oxygen vacancies of the catalyst. Among the catalysts tested, the NALC-60CA sample demonstrated a high conversion of 99.7% for ammonia decomposition at a gas hourly space velocity of 30,000 mL·h–1·g–1 and a temperature of 600 °C. Additionally, NALC-60CA exhibited good stability during a 55 h activity test at a temperature of 525 °C

Enhanced Immunosuppressive Capability of Mesenchymal Stem Cell-derived Small Extracellular Vesicles with High Expression of CD73 in Experimental Autoimmune Uveitis

Background: Autoimmune uveitis is an inflammatory disease triggered by an aberrant immune response. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) are emerging as potential therapeutic agents for this condition. CD73, an ectoenzyme present on MSC-sEVs, is involved in mitigating inflammation by converting extracellular adenosine monophosphate into adenosine. We hypothesize that the inhibitory effect of MSC-sEVs on experimental autoimmune uveitis (EAU) could be partially attributed to the surface expression of CD73.Methods: To investigate novel therapeutic approaches for autoimmune uveitis, we performed lentiviral transduction to overexpress CD73 on the surface of MSC-sEVs, yielding CD73-enriched MSC-sEVs (sEVs-CD73). Mice with interphotoreceptor retinoid-binding protein (IRBP)-induced EAU were grouped randomly and treated with 50 μg MSC-sEVs, vector infected MSC-sEVs, sEVs-CD73 or PBS via single tail vein injection. We evaluated the clinical and histological features of the induced mice and analyzed the proportion and functional capabilities of T helper cells. Furthermore, T-cells were co-cultured with various MSC-sEVs in vitro, and we quantified the resulting inflammatory response to assess the potential therapeutic benefits of sEVs-CD73.Results: Compared to MSC-sEVs, sEVs-CD73 significantly alleviates EAU, leading to reduced inflammation and diminished tissue damage. Treatment with sEVs-CD73 results in a decreased proportion of Th1 cells in the spleen, draining lymph nodes, and eyes, accompanied by an increased proportion of regulatory T-cells (Treg cells). In vitro assays further reveal that sEVs-CD73 inhibit T-cell proliferation, suppress Th1 cells differentiation, and enhance Treg cells proportion.Conclusion: Over-expression of CD73 on MSC-sEVs enhanced their immunosuppressive effects in EAU, indicating that sEVs-CD73 have the potential as an efficient immunotherapeutic agent for autoimmune uveitis.</p